Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and
Frankfurt: “6BX”) (the “
Company”
or “
Relevium”), and its’
wholly-owned subsidiary,
Biocannabix Health Corporation
(the “
BCX”), a company focused on
international research and development for cannabinoids,
nutraceuticals and medical food formulations, is pleased to
announce the appointment of Dr. Wolfgang Renz as Chief Scientific
Officer and Advisor.
Dr. Wolfgang Renz is a business executive
with expertise in medical innovation and cross-industry
convergence, and a practising physician. Dr. Renz holds an MD and
PhD from the University of Freiburg Medical School in Germany, and
graduated magna cum laude. Dr. Renz is currently a partner at
Tarmes Capital in Montreal, Canada; is a Senior Lecturer Executive
at the School of Management, Technology, and Law, University of
Sankt Gallen, Switzerland; is an Adjunct Professor of Experimental
Surgery in the Faculty of Medicine, McGill University, Montreal;
and is a Lt. Colonel (Reserve) in the German Armed Forces Medical
Services Command.
Dr. Renz has also been a Senior Research Fellow
at the Healthcare Innovation & Technology Lab in New York City
since 2012. From 2014 to 2015, he was President of International
Business at Physicians Interactive Holdings Inc., a provider of
online clinical resources for healthcare professionals, and from
2011 to 2014, Dr. Renz was Corporate Vice President of Boehringer
Ingelheim GmbH, a leading international pharmaceutical company. Dr.
Renz speaks German, English, and French. In addition to his
extensive work in for-profit and academic sectors, Dr. Renz has
also worked with the German Red Cross and the Peace Corps. Dr. Renz
serves on the board of several private and public
corporations.
Aurelio Useche, CEO of Relevium stated: “We are
extremely excited to welcome Dr. Renz as the leading force behind
all the current and on-going future scientific research and
development initiatives at Biocannabix. In addition to his role as
co-founder of IAM Health GmbH, Dr. Renz also runs a successful
medical practice in Germany, where he uses a wide range of
traditional and non-traditional therapeutical approaches for
patients with critical care needs, including advanced forms of
Cancer research and development. This perfectly aligns with the
long-term vision of our company”.
Dr. Wolfgang Renz commented: “In addition to the
combined opportunities with IAM Health GmbH, we are very excited to
continue the research and development of specific cannabinoid
formulations, nutraceuticals and medical food supplements, with a
particular focus on pediatric applications. This is an area of
development we are quite excited about, and I am delighted to be
joining the Biocannabix team”.
About Relevium Technologies
Relevium Technologies Inc., is
a publicly traded Company, focussed on international procurement,
logistics, and delivery of Personal Protective Equipment
(“PPE”) into the North American marketplace.
Utilizing trusted vendors and suppliers, and integrating a
comprehensive, state-of-the-art supply chain, Artificial
Intelligence (“AI”), and Blockchain technology, enables a highly
secure and compliant platform for delivery of PPE equipment to
Governments, Hospitals, Foundations, and various Institutions.
Biocannabix Health Corporation,
a wholly owned subsidiary of Relevium Technologies Inc., is focused
on Paediatric and Geriatric applications of Cannabinoid
formulations, nutraceuticals and medical food formulations. The
principal business of the Company is pursuing ongoing Research and
Development for the identification, evaluation, acquisition and
operation of brands and businesses in the health and wellness
markets and cannabinoid therapeutics.
Neither the
TSX Venture
Exchange nor its
Regulation Services Provider
(as that term
is defined in
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
Cautionary Note Regarding
Forward-Looking StatementsThis release includes certain
statements and information that may constitute forward-looking
information within the meaning of applicable Canadian securities
laws. All statements in this news release, other than statements of
historical facts, including statements regarding future estimates,
plans, objectives, assumptions or expectations of future
performance, including the timing and completion of the proposed
acquisitions, are forward-looking statements and contain
forward-looking information. Generally, forward- looking statements
and information can be identified by the use of forward-looking
terminology such as "intends" or "anticipates", or variations of
such words and phrases or statements that certain actions, events
or results "may", "could", "should", "would" or "occur".
Forward-looking statements are based on certain material
assumptions and analysis made by the Company and the opinions and
estimates of management as of the date of this press release,
including the assumptions that the Company will be able to apply
for and ultimately obtain an ACMPR licence, the proposed business
of Biocannabix will develop as anticipated, that the Company will
raise sufficient funds to develop the Biocannabix business, and
that the Company will obtain all requisite regulatory
approvals.
These forward-looking statements are subject to
known and unknown risks, uncertainties and other factors that may
cause the actual results, level of activity, performance or
achievements of the Company to be materially different from those
expressed or implied by such forward-looking statements or
forward-looking information. Important factors that may cause
actual results to vary, include, without limitation, the risk that
the proposed business developments may not occur as planned; the
timing and receipt of requisite approvals and failure to raise
sufficient funds.
Although management of the Company has attempted
to identify important factors that could cause actual results to
differ materially from those contained in forward-looking
statements or forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward- looking
statements and forward-looking information. Readers are cautioned
that reliance on such information may not be appropriate for other
purposes. The Company does not undertake to update any
forward-looking statement, forward-looking information or financial
outlook that are incorporated by reference herein, except in
accordance with applicable securities laws. We seek safe
harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES
INC.
Aurelio UsechePresident and CEO
For more information about this press release: Tel:
+1.888.528.8687
RELEVIUM TECHNOLOGIES INCEmail:
investors@releviumcorp.com Website: www.releviumtechnologies.com
Like us on FacebookFollow us on Twitter Follow us on LinkedIn
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jul 2023 to Jul 2024